Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Toronto, Ontario, Canada (PRWEB) September 30, 2014 ... requirements based on 500 square feet. per employee, which included ... different world back then.” says Jeff Howell, partner at ... tenant advisory firm in Toronto. “By the year 2000, ... We are now seeing that number come down to 175 ...
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Oligonucleotide Synthesis Market by Product & Services, End-User , ... their offering. The global oligonucleotide synthesis ... from $1,070.7 million in 2014, growing at a CAGR ... synthesis market is categorized on the basis of products ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
Breaking Biology Technology:ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2
... 11 Cardium Therapeutics,(Amex: CXM ) today ... http://www.anginaresearchstudy.com to provide patients, caregivers and,physicians with ... The AWARE study is evaluating the therapeutic effects ... (insufficient blood flow,within the heart muscle) and associated ...
... (HD) instruments recognized in premier program ... for the medical technology ... Systems,announced that the company,s RealHand High Dexterity (HD) instruments ... design,team did an excellent job thinking ,outside of the ...
... - RDEA119 Produced Significant Beneficial Effect in Animal Models of ... ... Effective Treatment for Gout -, SAN DIEGO, June 11 Ardea Biosciences, ... Company,s,lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating,its potent activity in animal models ...
Cached Biology Technology:Cardium Launches New AWARE Clinical Study Website 2Cardium Launches New AWARE Clinical Study Website 3Cardium Launches New AWARE Clinical Study Website 4Cardium Launches New AWARE Clinical Study Website 5Cardium Launches New AWARE Clinical Study Website 6Cardium Launches New AWARE Clinical Study Website 7Novare Surgical Wins Medical Design Excellence Award 2Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 2Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 3Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 4Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 5
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
Breaking Biology News(10 mins):Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... OCTOBER 27, 2009 -- Phosphorus is an essential element ... have led to massive eutrophication problems in water bodies ... is at least partly responsible for offshore "dead zones," ... of Mexico. While wetlands often act as filtering or ...
... 2009 -- Worldwide demand for a safe and secure ... forefront of sustainability discussions; however many research programs have ... traditional public or formula grants. Researchers are now turning ... international plant breeding programs. Stakeholders from public and ...
... management experts from across federal science agencies will gather ... identifying research priorities, exploring research performance management, and assessing ... meeting is to develop a collaborative framework to ensure ... in a coordinated manner. "We are bringing ...
Cached Biology News:Expert to discuss phosphorus' impact on Gulf 'dead zone' 2How do we fund plant breeding? 2How do we fund plant breeding? 3
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... Wide Range CRYETTE WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents ... cyclohexanol, sulfolane. ... ... ...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
Biology Products: